Sheep Polyclonal Factor X antibody. Suitable for IHC-P and reacts with Human samples. Immunogen corresponding to Native Full Length Protein corresponding to Human F10.
pH: 7.2
Constituents: 50% Glycerol (glycerin, glycerine)
IHC-P | |
---|---|
Human | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 5 µg/mL | Notes - |
Select an associated product type
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting (PubMed:22409427). Factor Xa activates pro-inflammatory signaling pathways in a protease-activated receptor (PAR)-dependent manner (PubMed:24041930, PubMed:30568593, PubMed:34831181, PubMed:18202198). Up-regulates expression of protease-activated receptors (PARs) F2R, F2RL1 and F2RL2 in dermal microvascular endothelial cells (PubMed:35738824). Triggers the production of pro-inflammatory cytokines, such as MCP-1/CCL2 and IL6, in cardiac fibroblasts and umbilical vein endothelial cells in PAR-1/F2R-dependent manner (PubMed:30568593, PubMed:34831181). Triggers the production of pro-inflammatory cytokines, such as MCP-1/CCL2, IL6, TNF-alpha/TNF, IL-1beta/IL1B, IL8/CXCL8 and IL18, in endothelial cells and atrial tissues (PubMed:24041930, PubMed:35738824, PubMed:9780208). Induces expression of adhesion molecules, such as ICAM1, VCAM1 and SELE, in endothelial cells and atrial tissues (PubMed:24041930, PubMed:35738824, PubMed:9780208). Increases expression of phosphorylated ERK1/2 in dermal microvascular endothelial cells and atrial tissues (PubMed:24041930, PubMed:35738824). Triggers activation of the transcription factor NF-kappa-B in dermal microvascular endothelial cells and atrial tissues (PubMed:24041930, PubMed:35738824). Activates pro-inflammatory and pro-fibrotic responses in dermal fibroblasts and enhances wound healing probably via PAR-2/F2RL1-dependent mechanism (PubMed:18202198). Activates barrier protective signaling responses in endothelial cells in PAR-2/F2RL1-dependent manner; the activity depends on the cleavage of PAR-2/F2RL1 by factor Xa (PubMed:22409427). Up-regulates expression of plasminogen activator inhibitor 1 (SERPINE1) in atrial tissues (PubMed:24041930).
Coagulation factor X, Stuart factor, Stuart-Prower factor, F10
Sheep Polyclonal Factor X antibody. Suitable for IHC-P and reacts with Human samples. Immunogen corresponding to Native Full Length Protein corresponding to Human F10.
pH: 7.2
Constituents: 50% Glycerol (glycerin, glycerine)
Factor Xa Heavy Chain sometimes referred to as 'anti Factor Xa' or 'anti FXa' plays a vital role in blood coagulation. This serine protease with a molecular mass around 43 kDa forms a critical part of the prothrombinase complex that converts prothrombin to thrombin. Factor Xa is widely expressed in the liver and circulates as an inactive zymogen in the bloodstream. Upon activation it becomes an important enzyme in the coagulation cascade driving the formation of a fibrin clot.
The Factor Xa Heavy Chain is essential for the propagation of the clotting response. It exists as part of a larger complex where Factor Xa binds with Factor Va on activated platelets. This complex formation dramatically increases the conversion rate of prothrombin to active thrombin. Through this mechanism Factor Xa is indispensable for effective hemostasis ensuring stable chlot formation in response to vascular injury. Furthermore because of its pivotal role it is often a target for anticoagulant drugs which can inhibit its activity and reduce clot formation in the body.
Factor Xa functions prominently in the coagulation cascade and the extrinsic pathway of blood coagulation. In these processes Factor Xa interacts importantly with Factor V to form the prothrombinase complex which accelerates the generation of thrombin. Thrombin then acts on fibrinogen resulting in fibrin clot formation. Additionally Factor Xa shares a pathway connection with tissue factor initiating the extrinsic pathway that rapidly advances the coagulation cascade following tissue injury.
Factor Xa has significant implications in thrombotic disorders like deep vein thrombosis and pulmonary embolism. An imbalance in its regulation can lead to excessive clot formation which poses serious health risks. Anticoagulants targeting Factor Xa help manage these conditions by blocking its activity and preventing thrombus progression. Additionally Factor Xa-related pathways involving proteins like Factor V play a role in hemophilia a disorder where coagulation is impaired highlighting the therapeutic importance of modulating Factor Xa activity in managing bleeding disorders.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
ab124289, at 5 μg/ml, staining Factor Xa Heavy Chain in paraffin embedded Human vessels by Immunohistochemistry.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com